1. Home
  2. ADVM vs BW Comparison

ADVM vs BW Comparison

Compare ADVM & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • BW
  • Stock Information
  • Founded
  • ADVM 2006
  • BW 1867
  • Country
  • ADVM United States
  • BW United States
  • Employees
  • ADVM N/A
  • BW N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • BW Building Products
  • Sector
  • ADVM Health Care
  • BW Industrials
  • Exchange
  • ADVM Nasdaq
  • BW Nasdaq
  • Market Cap
  • ADVM 47.4M
  • BW 45.3M
  • IPO Year
  • ADVM 2014
  • BW N/A
  • Fundamental
  • Price
  • ADVM $2.25
  • BW $0.99
  • Analyst Decision
  • ADVM Strong Buy
  • BW Buy
  • Analyst Count
  • ADVM 5
  • BW 2
  • Target Price
  • ADVM $26.40
  • BW $3.50
  • AVG Volume (30 Days)
  • ADVM 186.4K
  • BW 3.9M
  • Earning Date
  • ADVM 08-11-2025
  • BW 08-07-2025
  • Dividend Yield
  • ADVM N/A
  • BW N/A
  • EPS Growth
  • ADVM N/A
  • BW N/A
  • EPS
  • ADVM N/A
  • BW N/A
  • Revenue
  • ADVM $1,000,000.00
  • BW $734,239,000.00
  • Revenue This Year
  • ADVM N/A
  • BW $5.81
  • Revenue Next Year
  • ADVM $18.82
  • BW $9.24
  • P/E Ratio
  • ADVM N/A
  • BW N/A
  • Revenue Growth
  • ADVM N/A
  • BW 12.90
  • 52 Week Low
  • ADVM $1.78
  • BW $0.22
  • 52 Week High
  • ADVM $10.14
  • BW $2.99
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 40.11
  • BW 52.70
  • Support Level
  • ADVM $2.21
  • BW $0.76
  • Resistance Level
  • ADVM $3.10
  • BW $1.38
  • Average True Range (ATR)
  • ADVM 0.22
  • BW 0.18
  • MACD
  • ADVM -0.00
  • BW -0.03
  • Stochastic Oscillator
  • ADVM 4.49
  • BW 25.20

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: